Stock Performance and Market Context
On 12 Jan 2026, Krebs Biochemicals & Industries Ltd’s share price fell sharply, registering a day change of -6.95%, marking a fresh 52-week low. This decline comes despite the broader market’s positive movement, with the Sensex closing in green at 83,750.14, up 0.21% after recovering from an initial negative opening. The Sensex remains close to its 52-week high of 86,159.02, just 2.88% away, supported by gains in mega-cap stocks. In contrast, Krebs Biochemicals has underperformed significantly, with a one-year return of -32.65% compared to the Sensex’s 8.23% gain.
The stock’s performance today notably lagged its sector, underperforming the Pharmaceuticals & Biotechnology sector by -98.88%. Additionally, trading activity has been erratic, with the stock not trading on two days out of the last twenty, indicating low liquidity or investor hesitation. The share price currently trades below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a sustained downtrend.
Financial Metrics and Fundamental Assessment
Krebs Biochemicals & Industries Ltd’s financial health continues to show signs of strain. The company’s book value is negative, which contributes to a weak long-term fundamental strength rating. Over the past five years, net sales have declined at an annual rate of -11.65%, while operating profit has remained stagnant at 0%. This lack of growth is compounded by a high debt profile, with an average debt-to-equity ratio of 0 times, indicating reliance on debt financing.
Recent quarterly results have been negative for four consecutive quarters. The Profit After Tax (PAT) for the latest nine months stands at a loss of ₹19.73 crores, reflecting a decline of -58.24%. Net sales for the latest six months have also contracted sharply by -62.52%, amounting to ₹9.65 crores. The company’s debtor turnover ratio for the half-year is at a low 19.44 times, suggesting challenges in receivables management.
Just announced: This Small Cap from Tyres & Allied with precise target price is our pick for the week. Get the pre-market insights that informed this selection!
- - Just announced pick
- - Pre-market insights shared
- - Tyres & Allied weekly focus
Valuation and Risk Profile
The stock is considered risky relative to its historical valuations. Over the past year, profits have declined by -26.2%, while the stock price has fallen by -32.65%. This underperformance extends beyond the short term, with Krebs Biochemicals lagging behind the BSE500 index over the last three years, one year, and three months. The company’s EBITDA remains negative, further highlighting the financial pressures it faces.
Shareholding and Market Position
The majority shareholding remains with the promoters, indicating concentrated ownership. Despite this, the company’s market capitalisation grade is low at 4, reflecting its micro-cap status within the Pharmaceuticals & Biotechnology sector. The Mojo Score assigned to Krebs Biochemicals is 9.0, with a Mojo Grade of Strong Sell as of 6 Feb 2025, an upgrade from the previous Sell rating, signalling continued caution in the market’s view of the stock.
Krebs Biochemicals & Industries Ltd or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Comparative Sector and Market Analysis
While the Pharmaceuticals & Biotechnology sector has seen mixed performances, Krebs Biochemicals’ decline is more pronounced. The stock’s 52-week high was ₹113.9, highlighting the extent of the recent price erosion. In comparison, the Sensex’s resilience and proximity to its own 52-week high underscore the divergence between this micro-cap stock and broader market trends.
Summary of Key Financial Indicators
The company’s negative EBITDA and declining net sales over recent periods reflect ongoing financial strain. The negative PAT and weak debtor turnover ratio further illustrate challenges in profitability and cash flow management. These factors contribute to the stock’s current valuation and market sentiment.
Conclusion
Krebs Biochemicals & Industries Ltd’s fall to a 52-week low is a reflection of sustained financial pressures, weak growth metrics, and underperformance relative to both its sector and the broader market. The stock’s trading below all major moving averages and its strong sell rating highlight the cautious stance adopted by market participants. While the broader market and sector show signs of resilience, Krebs Biochemicals continues to face headwinds that have weighed on its share price over the past year.
Unlock special upgrade rates for a limited period. Start Saving Now →
